167 related articles for article (PubMed ID: 31478117)
1. miRNA-26a expression influences the therapy response to carmustine wafer implantation in patients with glioblastoma multiforme.
Sippl C; Ketter R; Braun L; Teping F; Schoeneberger L; Kim YJ; List M; Nakhoda A; Wemmert S; Oertel J; Urbschat S
Acta Neurochir (Wien); 2019 Nov; 161(11):2299-2309. PubMed ID: 31478117
[TBL] [Abstract][Full Text] [Related]
2. MiRNA-181d Expression Significantly Affects Treatment Responses to Carmustine Wafer Implantation.
Sippl C; Ketter R; Bohr L; Kim YJ; List M; Oertel J; Urbschat S
Neurosurgery; 2019 Jul; 85(1):147-155. PubMed ID: 29846701
[TBL] [Abstract][Full Text] [Related]
3. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort.
Pallud J; Audureau E; Noel G; Corns R; Lechapt-Zalcman E; Duntze J; Pavlov V; Guyotat J; Hieu PD; Le Reste PJ; Faillot T; Litre CF; Desse N; Petit A; Emery E; Voirin J; Peltier J; Caire F; Vignes JR; Barat JL; Langlois O; Dezamis E; Parraga E; Zanello M; Nader E; Lefranc M; Bauchet L; Devaux B; Menei P; Metellus P;
Neuro Oncol; 2015 Dec; 17(12):1609-19. PubMed ID: 26185110
[TBL] [Abstract][Full Text] [Related]
5. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
7. MiRNA-181d Expression Correlates in Tumor versus Plasma of Glioblastoma Patients-the Base of a Preoperative Stratification Tool for Local Carmustine Wafer Use.
Sippl C; Quiring A; Teping F; Schulz-Schaeffer W; Urbschat S; Ketter R; Oertel J
World Neurosurg; 2022 Mar; 159():e324-e333. PubMed ID: 34942386
[TBL] [Abstract][Full Text] [Related]
8. The Influence of Distinct Regulatory miRNAs of the p15/p16/RB1/E2F Pathway on the Clinical Progression of Glioblastoma Multiforme.
Sippl C; Teping F; Ketter R; Braun L; Tremmel L; Schulz-Schaeffer W; Oertel J; Urbschat S
World Neurosurg; 2019 Dec; 132():e900-e908. PubMed ID: 31351207
[TBL] [Abstract][Full Text] [Related]
9. Extent of resection and Carmustine wafer implantation safely improve survival in patients with a newly diagnosed glioblastoma: a single center experience of the current practice.
Roux A; Peeters S; Zanello M; Bou Nassif R; Abi Lahoud G; Dezamis E; Parraga E; Lechapt-Zalcmann E; Dhermain F; Dumont S; Louvel G; Chretien F; Sauvageon X; Devaux B; Oppenheim C; Pallud J
J Neurooncol; 2017 Oct; 135(1):83-92. PubMed ID: 28669011
[TBL] [Abstract][Full Text] [Related]
10. Safety and Effectiveness of Bis-Chloroethylnitrosourea Wafer Chemotherapy in Elderly Patients with Recurrent Glioblastoma.
Klein J; Juratli TA; Radev Y; Daubner D; Soucek S; Schackert G; Krex D
Oncology; 2017; 93(1):43-50. PubMed ID: 28395288
[TBL] [Abstract][Full Text] [Related]
11. Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series.
Subach BR; Witham TF; Kondziolka D; Lunsford LD; Bozik M; Schiff D
Neurosurgery; 1999 Jul; 45(1):17-22; discussion 22-3. PubMed ID: 10414561
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of carmustine wafers in the treatment of glioblastoma multiforme: a systematic review.
Zhang YD; Dai RY; Chen Z; Zhang YH; He XZ; Zhou J
Turk Neurosurg; 2014; 24(5):639-45. PubMed ID: 25269031
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival.
Chaichana KL; Zaidi H; Pendleton C; McGirt MJ; Grossman R; Weingart JD; Olivi A; Quiñones-Hinojosa A; Brem H
Neurol Res; 2011 Sep; 33(7):759-64. PubMed ID: 21756557
[TBL] [Abstract][Full Text] [Related]
14. Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma.
Giese A; Kucinski T; Knopp U; Goldbrunner R; Hamel W; Mehdorn HM; Tonn JC; Hilt D; Westphal M
J Neurooncol; 2004 Feb; 66(3):351-60. PubMed ID: 15015668
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.
Limentani SA; Asher A; Heafner M; Kim JW; Fraser R
J Neurooncol; 2005 May; 72(3):241-4. PubMed ID: 15937647
[TBL] [Abstract][Full Text] [Related]
16. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
Noël G; Schott R; Froelich S; Gaub MP; Boyer P; Fischer-Lokou D; Dufour P; Kehrli P; Maitrot D
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):749-55. PubMed ID: 21300471
[TBL] [Abstract][Full Text] [Related]
17. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.
Affronti ML; Heery CR; Herndon JE; Rich JN; Reardon DA; Desjardins A; Vredenburgh JJ; Friedman AH; Bigner DD; Friedman HS
Cancer; 2009 Aug; 115(15):3501-11. PubMed ID: 19514083
[TBL] [Abstract][Full Text] [Related]
18. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
19. Biodegradable wafers releasing Temozolomide and Carmustine for the treatment of brain cancer.
Shapira-Furman T; Serra R; Gorelick N; Doglioli M; Tagliaferri V; Cecia A; Peters M; Kumar A; Rottenberg Y; Langer R; Brem H; Tyler B; Domb AJ
J Control Release; 2019 Feb; 295():93-101. PubMed ID: 30605703
[TBL] [Abstract][Full Text] [Related]
20. microRNA-181a mediates the chemo-sensitivity of glioblastoma to carmustine and regulates cell proliferation, migration, and apoptosis.
Rezaei T; Hejazi M; Mansoori B; Mohammadi A; Amini M; Mosafer J; Rezaei S; Mokhtarzadeh A; Baradaran B
Eur J Pharmacol; 2020 Dec; 888():173483. PubMed ID: 32810491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
